CN116514838A - 苯并噁嗪螺吡咯烷酮类化合物的制备方法 - Google Patents

苯并噁嗪螺吡咯烷酮类化合物的制备方法 Download PDF

Info

Publication number
CN116514838A
CN116514838A CN202310480641.0A CN202310480641A CN116514838A CN 116514838 A CN116514838 A CN 116514838A CN 202310480641 A CN202310480641 A CN 202310480641A CN 116514838 A CN116514838 A CN 116514838A
Authority
CN
China
Prior art keywords
substituted
aryl
alkyl
preparation
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310480641.0A
Other languages
English (en)
Inventor
任海
彭玉生
石军
宋俊蓉
吴伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guizhou Natural Products Research Center
Original Assignee
Guizhou Natural Products Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guizhou Natural Products Research Center filed Critical Guizhou Natural Products Research Center
Priority to CN202310480641.0A priority Critical patent/CN116514838A/zh
Publication of CN116514838A publication Critical patent/CN116514838A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

本发明涉及一类苯并噁嗪螺吡咯烷酮类化合物的制备方法，苯并噁嗪是一类含有氮、氧六元的杂环化合物，具有广的生物活性和应用价值。一直以来，苯并噁嗪类化合物的合成方法相对较少，且往往需要多步合成。本发明以商业易得的N‑烷基‑四氢‑β‑咔啉为底物，在空气条件下，通过铜催化一步合成3,1‑苯并噁嗪螺吡咯烷酮类化合物。本发明的制备方法反应收率高，催化剂用量少，适用取代基范围广，操作简单，有望实现工业化应用前景。

Description

苯并噁嗪螺吡咯烷酮类化合物的制备方法
技术领域
本发明属于药物及药物中间体的制备技术领域，尤其涉及一类苯并噁嗪类化合物的制备方法。
背景技术
苯并噁嗪是一类含有氮、氧原子的杂环化合物，可根据杂原子取代位置的不同分为不同类别的苯并噁嗪。有1,3-苯并噁嗪、3,1-苯并噁嗪和1,4-苯并噁嗪等。苯并噁嗪类化合物具有广的生物活性，在抗虫、抗植物毒性、抗病性、化感等方面具有非常广的应用。其中，3,1-苯并噁嗪类化合物在抗心绞痛、降压作用、抗风湿和植物生长调节等方面也表现出强的生物活性(J.Med.Chem.1995,38,130；J.Med.Chem.1983,26,657；J.Med.Chem.1997,40,105；Chem.-Eur.J.2017,23,703；Molecules 2019,24,4165；Expert Opin.DrugDiscovery 2016,11,831)。
由于3,1-苯并噁嗪广的生物活性，近年来关于其合成研究也得到了一定的发展，目前已知的合成方法主要包括有：1)邻胺基苯甲醇及其衍生物经过氧化环化；2)邻胺基苯甲酸乙酯与RNCS或R2C＝NCN在碱性条件下环化加成；3)邻位双取代的苯胺通过多步反应与转化等方法(Tetrahedron Lett.1983,24,2213；Bioorg.Med.Chem.Lett.2002,12,787；Angew.Chem.Int.Ed.2008,47,4217；等)。已报到的方法合成工序均较复杂，步骤冗长，反应条件苛刻，往往需要当量的碱或氧化剂。此外，关于4,4-螺3,1-苯并噁嗪类化合物的合成方法目前还鲜有报道(J.Org.Chem.2021,86,4671)
综上所述，本领域尚缺乏一种反应操作简便、原料易得，原子经济性高、产物类型多样、能工业化合成3,1-苯并噁嗪的方法，该现状亟待解决。
发明内容
本发明意在提供一种3,1-苯并噁嗪螺吡咯烷酮类化合物的合成方法，以解决现有合成苯并噁嗪类化合物研究相对较少，且往往需要多步合成等问题。
为实现上述目的，本发明采用的技术方案是：3,1-苯并噁嗪螺吡咯烷酮类化合物的制备方法，加入溶剂，在催化量的铜盐的催化下，将结构式Ⅰ一步催化氧化得到结构式A，将所得产物依次进行过滤、旋转蒸发悬干和柱层析分离，得到3-碳环螺羟吲哚类化合物；
上述各式中，R1、R2、R3和R4各自独立为H、C1～C15烷基、取代的C1～C15烷基、C6～C15芳基、取代的C6～C15芳基、卤素、烷氧基或苄氧基；
R5、R6和R8各自独立为H、C1～C15烷基、取代的C1～C15烷基、C6～C15芳基、取代的C6～C15芳基、卤素、烷氧基或苄氧基，或通过取代成环；
R7和R9独立为H、C1～C15烷基、取代的C1～C15烷基、C6～C15芳基、取代的C6～C15芳基、苄基、取代的苄基、-COR1a、SO2R1a。
进一步的，所述R1a为C1～C15烷基、C6～C15芳基或取代的C6～C15芳基。
进一步的，所述铜盐催化剂为三氟甲磺酸铜、溴化铜、氯化铜和高氯酸铜中的一种或多种。
进一步的，所述制备方法，其特征在于，所述苯并噁唑啉配体为商业可得的双苯并噁唑啉配体或单苯并噁唑啉配体。
进一步的，所述双苯并噁唑啉配体的用量为式Ⅰ结构的化合物摩尔量的1～10％。
进一步的，所述结构式I结构的化合物、铜盐催化剂、双苯并噁唑啉配体和有机溶剂混合所得反应混合物中，结构式I结构的化合物的浓度为0.1～1mmol/L。
进一步的，所述反应的温度为25～60℃，时间为2～30h。
进一步的，所述溶解选自氯苯、乙腈、甲苯或其组合。
进一步的，所述柱层析分离所用洗脱剂为石油醚和乙酸乙酯的混合液，所述石油醚和乙酸乙酯的体积比为5:1～20:1。
本发明的有益技术效果是：本发明发现了一种全新的苯并噁嗪类化合物的合成方法，在少量铜盐的催化下，将结构式Ⅰ化合物直接一步催化氧化反应，从而得到苯并噁嗪类化合物。该方法具有原料简单，易得，底物适用范围广，操作简便，反应效率较高且仅需一步反应即可得到产物等优点。本发明制得的苯并噁嗪类化合物常表现出抗心绞痛、抗风湿和降压作用等生物活性，因此在医药领域有着十分重要的应用前景。
具体实施方式
下面将结合本发明实施例，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例1
实施例1将L(0.024mmol)，CuBr2(0.02mmol)，Cu(OAc)2(0.02mmol)，加入到25mL反应管中，加入3ml混合溶剂甲苯:乙腈＝2:1，在常温下搅拌2h,然后加入原料1-1(0.2mmol)及H2O(8.0mmol)，将温度升至60℃，继续搅拌反应，TLC跟踪至原料1-1消失。制得产物A-1，产率为77％。
制备得到的A-1的核磁共振(1H NMR和13C NMR)和高分辨质谱检测数据为：黄色固体,24h,46.8mg,77％yield.1H NMR(600MHz,Chloroform-d)δ7.37(t,J＝7.2Hz,2H),7.34-7.28(m,3H),7.17-7.13(m,1H),6.90-6.86(m,2H),6.82(d,J＝8.8Hz,1H),5.25(d,J＝9.6Hz,1H),4.65(d,J＝14.6Hz,2H),4.47(d,J＝14.6Hz,1H)，4.34(brs,1H),3.48-3.43(m,1H),3.34-3.29(m,1H),2.49-2.39(m,2H)ppm.13C NMR(150MHz,Chloroform-d)δ173.9,142.2,136.4,129.1，128.5,128.4,128.1,125.9,125.7,121.3,119.6,80.0,71.6,47.0,43.0,35.1ppm。
2-20的具体实施方式，参考实施例1，部分代表性化合物的核磁共振(1H NMR和13CNMR)数据如下：
实施例2：
A-2浅黄色固体,15h,47.3mg,73％yield.1HNMR(600MHz,Chloroform-d)δ7.23(d,J＝8.6Hz,2H),7.14(t,J＝8.2Hz,1H),6.92-6.84(m,4H),6.81(d,J＝8.0Hz,1H),5.24(d,J＝9.6Hz,1H),4.64(d,J＝9.6Hz,1H),4.60(d,J＝14.6Hz,1H),4.40(d,J＝14.6Hz,1H),4.33(brs,1H),3.82(s,3H),3.46-3.40(m,1H),3.32-3.27(m,1H),2.47-2.37(m,2H)ppm.13C NMR(150MHz,Chloroform-d)δ173.8,159.7,142.2,129.9,128.5,128.4,126.0,125.7,121.4,119.6,114.4,80.0,71.6,55.2,46.4,42.8,35.1ppm.
实施例3：
A-3浅黄色固体,23h,47.8mg,70％yield.1H NMR(600MHz,Chloroform-d)δ8.23(d,J＝8.6Hz,2H),7.46(d,J＝8.6Hz,2H),7.15(t,J＝8.4Hz,1H),6.91-6.86(m,2H),6.81(d,J＝8.0Hz,1H),5.19(d,J＝9.6Hz,1H),4.70-4.62(m,3H),4.44(brs,1H),3.53-3.49(m,1H),3.37-3.32(m,1H),2.54-2.43(m,2H)ppm.13C NMR(150MHz,Chloroform-d)δ173.7,147.5,143.6,141.9,128.7,128.2,125.3,124.7,124.0,120.9,119.2,79.6,71.5,46.6,43.5,35.3ppm
实施例4：
A-4浅黄色固体，23h,43.3mg,66％yield.1HNMR(600MHz,Chloroform-d)δ7.34(d,J＝8.4Hz,2H),7.23(d,J＝8.4Hz,2H),7.15(t,J＝8.4Hz,1H),6.89(t,J＝7.6Hz,1H),6.85(d,J＝7.8Hz,1H),6.82(d,J＝8.2Hz,1H),5.22(d,J＝9.6Hz,1H),4.64(d,J＝9.6Hz,1H),4.58(d,J＝14.8Hz,1H),4.47(d,J＝14.8Hz,1H),3.48–3.41(m,1H),3.34–3.27(m,1H),2.51–2.38(m,2H)ppm.13C NMR(150MHz,Chloroform-d)δ173.4,141.8,134.6,133.6,129.6,129.0,128.2,125.4,125.3,121.0,119.3,79.8,71.6,46.6,43.2,35.3ppm.
实施例5：
A-5浅黄色固体,48h,35.3mg,60％yield.1HNMR(600MHz,Chloroform-d)δ7.19–7.16(m,4H),7.13–7.10(m,1H),6.88–6.84(m,2H),6.78(d,J＝8.6Hz,1H),5.20(d,J＝9.6Hz,1H),4.63–4.60(m,2H),4.41(d,J＝14.6Hz,1H),3.44–3.40(m,1H),3.31–3.27(m,1H),2.46–2.35(m,2H),2.35(s,3H)ppm.13C NMR(150MHz,Chloroform-d)δ173.3,141.8,137.4,133.0,129.4,128.2,128.0,125.5,125.3,120.9,119.2,80.0,71.5,46.9,43.0,35.3,21.1ppm.
实施例6：
A-6浅黄色固体,46h,39.3mg,60％yield.1HNMR(600MHz,Chloroform-d)δ7.30–7.28(m,3H),7.19–7.16(m,1H),7.15–7.12(m,1H),6.90–6.85(m,2H),6.80(d,J＝8.0Hz,1H),5.20(d,J＝9.6Hz,1H),4.64(d,J＝9.6Hz,1H),4.58(d,J＝14.8Hz,1H),4.47(d,J＝14.8Hz,1H),4.37(brs,1H),3.48–3.44(m,1H),3.33–3.30(m,1H),2.50–2.40(m,2H)ppm.13C NMR(150MHz,Chloroform-d)δ173.5,141.85,138.1,134.6,130.1,128.2,128.2,128.0,126.3,125.4,125.3,121.1,119.3,79.8,71.6,46.7,43.3,35.3ppm.
实施例7：
A-7黄色固体，46h,46.8mg,61％yield.1HNMR(600MHz,Chloroform-d)δ7.84(s,1H),7.78(d,J＝8.6Hz,1H),7.44(s,1H),7.36(d,J＝10.6Hz,1H),7.17–7.13(m,1H),6.87(t,J＝7.6Hz,1H),6.83–6.80(m,2H),5.23(d,J＝9.6Hz,1H),4.89(d,J＝14.8Hz,1H),4.67–4.63(m,2H),3.44–3.40(m,1H),3.25–3.21(m,1H),2.42–2.35(m,3H)ppm.13C NMR(150MHz,Chloroform-d)δ173.2,141.9,138.9,138.6,131.1,130.6,128.16,127.3,125.6,125.3,125.0,123.8,121.9,121.2,119.2,80.1,71.7,43.1,41.0,35.3ppm.
实施例8：
A-8黄色固体,46h,26.1mg,37％yield.1H NMR(600MHz,Chloroform-d)δ7.13(t,J＝8.4Hz,1H),6.89–6.84(m,2H),6.79(d,J＝8.4Hz,1H),6.76(d,J＝2.2Hz,1H),6.38(d,J＝3.4Hz,1H),5.16(d,J＝9.6Hz,1H),4.71(d,J＝15.6Hz,1H),4.63(d,J＝9.6Hz,1H),4.48(d,J＝15.6Hz,1H),3.60–3.56(m,1H),3.49–3.45(m,1H),2.54–2.42(m,2H)ppm.13C NMR(150MHz,Chloroform-d)δ173.3,152.7,141.7,128.2,125.2,125.0,121.1,119.2,112.6,112.5,109.3,79.5,71.6,43.8,39.8,35.4ppm.
实施例9：
A-9浅黄色固体，24h,43.2mg,57％yield.1HNMR(600MHz,Chloroform-d)δ7.27(d,J＝6.2Hz,1H),7.13(t,J＝6.8Hz,1H),6.93(d,J＝5.6Hz,1H),6.88–6.83(m,2H),6.79(d,J＝8.6Hz,1H),5.19(d,J＝9.6Hz,1H),4.63–4.59(m,2H),4.47(d,J＝14.8Hz,1H),4.39(brs,1H),3.49–3.45(m,1H),3.36–3.32(m,1H),2.48–2.38(m,2H)ppm.13C NMR(150MHz,Chloroform-d)δ173.2,141.8,135.8,128.2,128.1,126.6,125.4,121.0,119.2,111.8,79.7,71.6,43.3,41.1,35.3ppm.
实施例10：
A-10浅黄色固体,24h,38.6mg,51％yield.1H NMR(600MHz,Chloroform-d)δ7.32(d,J＝8.6Hz,2H),7.21(d,J＝8.2Hz,2H),7.14–7.12(m,1H),6.89–6.83(m,2H),6.80(d,J＝8.0Hz,1H),5.19(d,J＝9.6Hz,1H),4.63(d,J＝9.6Hz,1H),4.59(d,J＝14.8Hz,1H),4.52(d,J＝14.8Hz,1H),4.47(brs,1H),3.48–3.44(m,1H),3.34–3.30(m,1H),2.50–2.40(m,2H)ppm.13C NMR(150MHz,Chloroform-d)δ173.5,148.7,141.8,134.82,129.5,128.2,125.3,125.1,121.3,120.9,119.5,119.2,79.7,71.5,46.4,43.2,35.3ppm.19F NMR(565MHz,Chloroform-d)δ-57.85ppm.
实施例11：
A-11浅黄色固体,24h,39.3.6mg,61％yield.1H NMR(600MHz,Chloroform-d)δ7.13–7.11(m,1H),6.94(s,1H),6.90(s,2H),6.86(d,J＝4.2Hz,2H),6.79(d,J＝8.0Hz,1H),5.23(d,J＝8.8Hz,1H),4.64–4.60(m,2H),4.45(brs,1H),4.34(d,J＝14.6Hz,1H),3.45–3.41(m,1H),3.32–3.29(m,1H),2.47–2.37(m,2H),2.31(s,6H)ppm.13C NMR(150MHz,Chloroform-d)δ173.3,141.8,138.3,135.9,129.3,128.0,126.0,125.6,125.3,120.8,119.1,80.0,71.6,47.1,43.1,35.2,21.2ppm.
实施例12：
A-12黄色固体,24h,23.9mg,49％yield.1H NMR(600MHz,Chloroform-d)δ7.14–7.11(m,1H),6.91–6.87(m,2H),6.78(d,J＝8.2Hz,1H),5.83–5.77(m,1H),5.29–5.25(m,2H),5.16(d,J＝9.6Hz,1H),4.62(d,J＝9.6Hz,1H),4.41(s,1H),4.05–3.94(m,2H),3.55–3.51(m,1H),3.43–3.40(m,1H),2.52–2.41(m,2H)ppm.13C NMR(150MHz,Chloroform-d)δ173.1,141.8,131.9,128.0,125.4,125.3,120.9,119.2,118.4,80.0,71.6,45.8,43.3,35.4ppm.
实施例13：
A-13白色固体,22h,32.1mg,59％yield.1H NMR(600MHz,Chloroform-d)δ7.14–7.11(m,1H),6.90–6.87(m,2H),6.79(d,J＝8.2Hz,1H),5.22–5.18(m,2H),4.62(d,J＝9.6Hz,1H),4.06–3.90(m,2H),3.52–3.38(m,2H),2.50–2.38(m,2H),1.77(s,3H),1.73(s,3H)ppm.13C NMR(150MHz,Chloroform-d)δ172.8,141.8,137.7,128.0,125.7,125.4,121.0,119.2,118.1,80.1,71.6,43.1,40.8,35.4,25.7,17.9ppm.
实施例14：
A-14浅黄色固体,22h,30.5mg,56％yield.1H NMR(600MHz,Chloroform-d)δ7.14–7.11(m,1H),6.90–6.86(m,2H),6.79(d,J＝8.0Hz,1H),5.17(d,J＝9.6Hz,1H),4.63(d,J＝9.6Hz,1H),4.57–4.52(m,1H),3.55–3.51(m,1H),3.45–3.41(m,1H),2.50–2.39(m,2H),1.95–1.89(m,2H),1.77–1.72(m,2H),1.67–1.61(m,4H)ppm.13C NMR(150MHz,Chloroform-d)δ173.1,141.7,128.0,125.7,125.3,121.0,119.2,80.5,71.6,53.1,39.6,35.5,29.1,28.6,24.2ppm.
实施例15：
A-15白色固体,17h,31.4mg,49％yield.1H NMR(600MHz,Chloroform-d)δ7.39(d,J＝7.2Hz,2H),7.33(t,J＝7.6Hz,2H),7.28–7.25(m,1H),7.13(t,J＝8.4Hz,1H),6.93–6.87(m,2H),6.79(d,J＝8.4Hz,1H),6.60(d,J＝15.8Hz,1H),6.20–6.15(m,1H),5.19(d,J＝9.6Hz,1H),4.63(d,J＝9.6Hz,1H),4.41(brs,1H),4.21–4.10(m,2H),3.59–3.44(m,2H),2.53–2.41(m,2H)ppm.13C NMR(150MHz,Chloroform-d)δ173.1,141.8,136.2,133.9,128.6,128.1,127.9,126.4,125.4,125.3,123.3,120.9,119.2,80.0,71.6,45.4,43.3,35.4ppm.
实施例16：
A-16浅黄色固体,23h,27.9mg,43％yield.1H NMR(600MHz,Chloroform-d)δ7.38–7.34(m,2H),7.31(t,J＝6.4Hz,3H),6.84(d,J＝8.8Hz,1H),6.77(dd,J＝8.8,2.8Hz,1H),6.38(d,J＝2.8Hz,1H),5.16(d,J＝10.0Hz,1H),4.68(d,J＝14.6Hz,1H),4.60(d,J＝10.0Hz,1H),4.44(d,J＝14.4Hz,1H),4.09(brs,1H),3.68(s,3H),3.48–3.43(m,1H),3.34–3.30(m,1H),2.48–2.38(m,2H)ppm.13C NMR(150MHz,Chloroform-d)δ173.2,155.0,136.1,135.0,128.8,128.3,128.1,127.8,122.3,114.5,110.2,79.8,72.3,55.5,47.3,43.2,35.4ppm.
实施例17：
A-17浅黄色固体,24h,45.6mg,69％yield.1H NMR(600MHz,Chloroform-d)δ7.38(t,J＝7.4Hz,2H),7.33–7.28(m,3H),7.06(dd,J＝8.6,2.4Hz,1H),6.81(d,J＝2.4Hz,1H),6.69(d,J＝8.6Hz,1H),5.16(d,J＝4.4Hz,1H),4.64(d,J＝14.6Hz,1H),4.59(d,J＝4.4Hz,1H),4.48(d,J＝14.6Hz,1H),3.46–3.42(m,1H),3.32–3.28(m,1H),2.45–2.36(m,2H)ppm.13C NMR(150MHz,Chloroform-d)δ172.8,140.4,135.8,128.9,128.2,128.2,127.8,126.5,125.5,125.1,120.3,79.7,71.4,47.3,43.1,35.1ppm.
实施例18：
A-18浅黄色液体,27h,32.6mg,57％yield.1H NMR(600MHz,Chloroform-d)δ7.13–7.01(m,1H),6.87(d,J＝4.4Hz,2H),6.78(d,J＝8.2Hz,1H),5.17(d,J＝9.6Hz,1H),4.62(d,J＝9.6Hz,1H),4.39(brs,1H),4.03–3.98(m,1H),3.54–3.50(m,1H),3.44–3.40(m,1H),2.48–2.37(m,2H),1.85–1.80(m,4H),1.52–1.45(m,2H),1.44–1.33(m,4H)ppm.13C NMR(150MHz,Chloroform-d)δ172.6,141.7,127.9,125.8,125.2,120.9,119.2,80.4,71.6,51.2,39.5,35.6,30.4,29.9,25.4,25.4,25.3ppm.
实施例19：
A-19浅黄色液体,46h,32.2mg,56％yield.1H NMR(600MHz,Chloroform-d)δ7.14–7.11(m,1H),6.89–6.85(m,2H),6.79(d,J＝8.2Hz,1H),5.15(d,J＝9.6Hz,1H),4.62(d,J＝9.6Hz,1H),4.42(brs,1H),4.30–4.25(m,1H),4.07–4.03(m,2H),3.54–3.43(m,4H),2.51–2.41(m,2H),1.89–1.82(m,2H),1.74–1.70(m,2H)ppm.13C NMR(150MHz,Chloroform-d)δ172.9,141.7,128.1,125.3,125.2,120.9,119.2,80.3,71.6,67.0,67.0,48.4,39.6,35.5,30.1,29.6ppm.
实施例20：
A-20浅黄色固体,16h,35.4mg,53％yield.1H NMR(600MHz,Chloroform-d)δ7.24–7.18(m,3H),7.14–7.11(m,1H),7.08(d,J＝7.4Hz,1H),6.93–6.87(m,2H),6.79(d,J＝7.8Hz,1H),6.57(d,J＝15.8Hz,1H),6.16(dt,J＝15.8,6.8Hz,1H),5.19(d,J＝9.6Hz,1H),4.63(d,J＝9.6Hz,1H),4.40(brs,1H),4.20–4.17(m,1H),4.13–4.10(m,1H),3.59–3.55(m,1H),3.47–3.44(m,1H),2.52–2.41(m,2H),2.35(s,3H)ppm.13C NMR(150MHz,Chloroform-d)δ173.0,141.8,138.2,136.2,134.0,128.7,128.5,128.1,127.1,125.4,125.4,123.6,123.1,121.0,119.2,80.1,71.6,45.4,43.3,35.4,21.3ppm。
最后所应说明的是：以上实施例仅用以说明而非限制本发明的技术方案，尽管参照上述实施例对本发明进行了详细说明，本领域的普通技术人员应该理解：依然可以对本发明进行修改或者等同替换，而不脱离本发明的精神和范围的任何修改或局部替换，其均应涵盖在本发明的权利要求范围当中。

Claims (10)

1.3,1-苯并噁嗪螺吡咯烷酮类化合物的制备方法，其特征在于，加入溶剂，在催化量的铜盐的催化下，将结构式Ⅰ一步催化氧化得到结构式A，
上述各式中，R1、R2、R3和R4各自独立为H、C1～C15烷基、取代的C1～C15烷基、C6～C15芳基、取代的C6～C15芳基、卤素、烷氧基或苄氧基；
R5、R6和R8各自独立为H、C1～C15烷基、取代的C1～C15烷基、C6～C15芳基、取代的C6～C15芳基、卤素、烷氧基或苄氧基，或通过取代成环；
R7和R9独立为H、C1～C15烷基、取代的C1～C15烷基、C6～C15芳基、取代的C6～C15芳基、苄基、取代的苄基、-COR1a、SO2R1a。
2.根据权利要求1所述制备方法，其特征在于，所述R1a为C1～C15烷基、C6～C15芳基或取代的C6～C15芳基。
3.根据权利要求1所述制备方法，其特征在于，所述铜盐催化剂为三氟甲磺酸铜、溴化铜、氯化铜和高氯酸铜中的一种或多种。
4.根据权利要求1所述制备方法，其特征在于，所述苯并噁唑啉配体为商业可得的双苯并噁唑啉配体或单苯并噁唑啉配体。
5.根据权利要求1所述制备方法，其特征在于，所述双苯并噁唑啉配体的用量为结构式Ⅰ结构的化合物摩尔量的1～10％。
6.根据权利要求1所述制备方法，其特征在于，所述结构式I结构的化合物、铜盐催化剂、双苯并噁唑啉配体和有机溶剂混合所得反应混合物中，结构式I结构的化合物的浓度为0.1～1mmol/L。
7.根据权利要求1所述制备方法，其特征在于，所述反应的温度为25～60℃，时间为2～30h。
8.根据权利要求1所述制备方法，其特征在于，所述溶解选自氯苯、乙腈、甲苯或其组合。
9.根据权利要求1所述制备方法，其特征在于，完成所述反应后，还包括：将所得产物依次进行过滤、旋转蒸发悬干和柱层析分离，得到3-碳环螺羟吲哚类化合物。
10.根据权利要求8所述制备方法，其特征在于，所述柱层析分离所用洗脱剂为石油醚和乙酸乙酯的混合液，所述石油醚和乙酸乙酯的体积比为5:1～20:1。
CN202310480641.0A 2023-04-28 2023-04-28 苯并噁嗪螺吡咯烷酮类化合物的制备方法 Pending CN116514838A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310480641.0A CN116514838A (zh) 2023-04-28 2023-04-28 苯并噁嗪螺吡咯烷酮类化合物的制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310480641.0A CN116514838A (zh) 2023-04-28 2023-04-28 苯并噁嗪螺吡咯烷酮类化合物的制备方法

Publications (1)

Publication Number Publication Date
CN116514838A true CN116514838A (zh) 2023-08-01

Family

ID=87398867

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310480641.0A Pending CN116514838A (zh) 2023-04-28 2023-04-28 苯并噁嗪螺吡咯烷酮类化合物的制备方法

Country Status (1)

Country Link
CN (1) CN116514838A (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114907254A (zh) * 2021-12-15 2022-08-16 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种3-碳环螺羟吲哚类化合物的制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114907254A (zh) * 2021-12-15 2022-08-16 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种3-碳环螺羟吲哚类化合物的制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KHUZHAEV, V. U.: "Alkaloids of the flora of Uzbekistan, Arundo donax", CHEMISTRY OF NATURAL COMPOUNDS, vol. 40, no. 2, pages 160 - 162 *
MADINAVEITIA, J.: "Alkaloids of Arundo donax L", JOURNAL OF THE CHEMICAL SOCIETY, pages 1927 - 1929 *
V. U. KHUZHAEV,: "Alkaloids of Arundo donax. IV. Donaxanine, a new pyrrolidine alkaloid from Arundo donax", CHEMISTRY OF NATURAL COMPOUNDS, vol. 31, no. 5, pages 610 - 611 *

Similar Documents

Publication Publication Date Title
CN114315823B (zh) 盐酸小檗碱及其类似物的中间体及其制备方法
US6197998B1 (en) Process for producing N-glycyltyrosine and its crystal structure
US5498711A (en) Synthesis of 4,10-dinitro-2,6,8,12-tetraoxa-4,10-diazatetracyclo[5.5.0.05,903,11]dodecane
CN116514838A (zh) 苯并噁嗪螺吡咯烷酮类化合物的制备方法
CN100408554C (zh) 高纯度肼基碳酸甲酯的合成新工艺
RU2620379C2 (ru) СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ 2-ФЕНИЛ[1,2,4]ТРИАЗОЛО[1,5-а]ПИРИДИНА
CN108191737B (zh) N-(2-甲硫基苯基)异吲哚-1,3-二酮化合物的制备方法
CN112592306A (zh) 吡咯啉酮类化合物及其合成方法
US4017533A (en) Diaminomaleonitrile derivatives and processes for preparing the same
CN113200902B (zh) 一种多取代吡咯衍生物及其制备方法
CN109467558B (zh) 1-氢吡咯嗪衍生物及其合成方法和应用
CN111320579B (zh) 一种8-酰胺-5-卤代喹啉衍生物的制备方法
CN113416166B (zh) 一种制备4-羟基喹啉-2（1h）-酮类化合物的方法
CN114805208A (zh) 一种4-三氟甲基-4,5-二氢吡唑衍生物及其制备方法
CA1102332A (en) Intermediate product for the production of 6,7- dimethoxy-4-amino-2-¬4-(2-furoyl)-1- piperazinyl|quinazoline having an antihypertensive effect
CN112778198A (zh) 一种二氢喹啉酮化合物的合成方法
KR820000868B1 (ko) 2-메틸-2-하이드록시 프로필 피페라진-1카복실 레이트 화합물의 제조 방법
Zhang et al. A new variant of Knorr's pyrrole synthesis
JP2021181407A (ja) アミドアルコール化合物の水和物及びその製造方法、並びに、及びラクトン化合物の製造方法
EP4214201A1 (en) Preparation method of substituted pyrimidine piperazine compounds
CN114478454A (zh) Sglt2抑制剂关键中间体以及其制备方法
CN115784967A (zh) 硝基异吲哚啉酮类化合物的合成方法
CN117466915A (zh) 一种含色酮苯并[d]咪唑并[2,1-b]噻唑化合物及其制备方法和应用
CN115403506A (zh) 一种吲哚-2-羧酸类衍生物的制备方法
JPS63211264A (ja) インドリン類の製造法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination